21
May
2008
Array BioPharma (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) recently announced plans for two additional randomized Phase II trials for ARRY-886, an oncology small molecule inhibitor targeting the Ras/Raf/MEK/ERK signaling pathway. The trials, scheduled to initiate in 2H08, will test ARRY-886 in combination with chemotherapeutic agents in melanoma and non small cell lung cancer patients. Recall [...]
06
May
2008
With over $116M in cash on the books as-of 31 March that did not keep management at Array BioPharma (NASDAQ: ARRY) from securing an additional $80M debt facility from Deerfield Management. Deerfield currently holds in excess of 4.7M shares of Array or nearly 10% of the company. This new debt round will be drawn down [...]
05
Mar
2008
Great news from Array Biopharma (NASDAQ: ARRY) re: Phase II results from the ARRY-797 asset, a small molecule p38-alpha inhibitor which modulates the production of TNF, IL-1 and IL-6 inflammatory mediators and the PGE2 pain mediator. The post-surgical molar extraction dental pain study achieved all of its total pain relief endpoints for analgesic efficacy. ARRY-797 [...]
05
Feb
2008
Array Q’ly Report: Well Positioned!
Posted in CO Pub Rel: AstraZeneca, CO Pub Rel: Celgene, CO Pub Rel: Roche, CO Public: Array
Array Biopharma (NASDAQ: ARRY) is an incredibly well positioned tour de force biopharmaceutical company with a strong balance sheet, a vast portfolio of six wholly owned compounds, and a variety of pharma partnered development efforts with AstraZeneca (NYSE: AZN), Celgene (NASDAQ: CELG), InterMune (NASDAQ: ITMN) and Roche (Swiss: RO.SW). President and CEO Robert Conway and [...]
11
Jan
2008
A few weeks back I posted (here) about the news on Array BioPharma’s (NASDAQ: ARRY) outcome for ARRY-886 and the response Wall Street was having as well as AstraZeneca (NYSE: AZN), Array’s development partner, and Schering Plough (NYSE: SGP) and their competitive oncology product, reactions . My argument was that matching standard of care as [...]
21
Dec
2007
Many are reeling from today’s near 28% plunge in Array’s (NASDAQ: ARRY) stock price based upon the news of a failed Phase II for ARRY-886…ummm, is the street calling it failure…people please, hold on there for a moment! What exactly happened in the Mek inhibitor molecule study of this first in class novel therapy used [...]
15
Nov
2007
Array Biopharma (NASDAQ: ARRY) is really hitting on all cylinders with eight-wholly owned development programs and a rich portfolio of discovery programs. Let’s take a closer look under the hood…shall we?ARRY 162 – neared completion of a Phase I trial with of adding to methotrexate in patients with stable rheumatoid arthritis. Plans are to begin [...]
27
Sep
2007
Celgene Makes Ya Go Hmmm…
Posted in CO Private: GlobeImmune, CO Pub Rel: Celgene, CO Public: Array, CO Public: Pharmion
Just what I think to be an interesting observation…that is how deep New Jersey-based Celgene (NASDAQ: CELG) has penetrated into the Colorado bio-scape. The connection appears to have initiated back in 2001 on a licensing deal with Pharmion (NASDAQ: PHRM) for Thalomid® (BTW…take a listen to Pharmion’s UBS Global Life Sciences Conference presentation from today [...]
24
Sep
2007
Array BioPharma, Inc. (NASDAQ: ARRY) and Celgene Corp. (NASDAQ: CELG) announced a worldwide strategic collaboration focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation. Celgene will make an upfront payment of $40MM to Array, in return Array will grant Celgene an option to select drugs developed under the collaboration that [...]
12
Sep
2007
Colorado Public Company News:
Posted in CO Public: Accelr8, CO Public: Allos Therapeutics, CO Public: Array, CO Public: Aspen BioPharma, CO Public: Ceragenix Pharma, CO Public: Encision, CO Public: Heska, CO Public: Tapestry Pharma
By my calculations there are ten publicly traded CO-based life science companies. I will begin a regular update of this group. Another group of public companies are operating in or have other significant interests or relationships with entities in Colorado. This group includes Amgen (NASDAQ: AMGN), Gilead (NASDAQ: GILD), Merck (NYSE: MRK), Roche (VTX: ROG.VX) [...]
14
Aug
2007
Array BioPharma, Inc. (NASDAQ: ARRY) plans to initiate a Phase I trial this fall for ARRY-380, a selective, orally-active ErbB-2 inhibitor for metastatic breast cancer patients and perhaps those who are resistant to Genentech’s (NYSE: DNA) HER2 targeting blockbuster Herceptin. The ARRY-380 candidate ErbB-2 inhibitor has shown efficacy and is well-tolerated in pre-clinical models of [...]
10
Nov
2006
Data Data Data…
Posted in CO Public: Array
We can thank the Tufts Center for the Study of Drug Development for officially estimating the cost to bring a biotech product to market, that is $1.2B, with average preclinical costs of $615M and clinical costs of $626M, and requires just over eight years to bring to market. Note: Average out-of-pocket cost per approved biopharmaceutical [...]
06
Nov
2006
Two fantastic tidbits emerging out of Array Biopharma, Inc. (NASDAQ: ARRY) headquarters: Array has filed an Investigational New Drug application for ARRY-797 with the FDA and is now able to proceed with human clinical studies. ARRY-797 is a potent, selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy [...]
Life Science Deal Flow PARTNERS
-
